Education
About Us
Working with TipRanks
Follow Us
Danaher Corp. (DHR)
NYSE:DHR
DHR Stock Chart & Stats
$221.21
-$1.72(-0.72%)
At close: 4:00 PM EST
$221.21
-$1.72(-0.72%)
Day’s Range― - ―
52-Week Range$171.00 - $258.23
Previous CloseN/A
Volume816.38K
Average Volume (3M)3.88M
Market Cap
$156.25B
Enterprise Value$148.56B
Total Cash (Recent Filing)$1.53B
Total Debt (Recent Filing)$16.86B
Price to Earnings (P/E)45.5
Beta0.92
Next Earnings
Feb 04, 2026EPS Estimate
2.14Last Dividend Ex-Date
Sep 26, 2025Dividend Yield0.56%
Share Statistics
EPS (TTM)1.89
Shares Outstanding706,349,550
10 Day Avg. Volume3,626,761
30 Day Avg. Volume3,880,220
Financial Highlights & Ratios
PEG Ratio-2.50
Price to Book (P/B)3.39
Price to Sales (P/S)7.03
P/FCF Ratio31.68
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue6.12
Enterprise Value/Gross Profit9.97
Enterprise Value/Ebitda21.64
Forecast
1Y Price Target
$243.45Price Target Upside10.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)7.72
Revenue Forecast (FY)$24.53B
Bulls Say, Bears Say
Bulls Say
Earnings PerformanceDanaher’s third-quarter results were better than expectations, including a beat on both the top and bottom line.
Operational EfficiencyAdjusted operating margin improved year-over-year and sequentially, indicating better operational efficiency.
Share Buyback ProgramDanaher executed a significant share buyback program, repurchasing 10 million shares valued at approximately $2 billion.
Bears Say
2025 Core Revenue GrowthDanaher has lowered its 2025 non-GAAP core revenue growth guidance, implying a reduction to low single-digit growth.
2025 Growth GuidanceFor 2025, Danaher reiterated its guidance despite the beat and now expects core growth to be in the low single digits.
Life Sciences And Diagnostics SegmentsWeak spots exist in Life Sciences and China Diagnostics, which are assumed in the guide.
Danaher News
DHR FAQ
What was Danaher Corp.’s price range in the past 12 months?
Danaher Corp. lowest stock price was $171.00 and its highest was $258.23 in the past 12 months.
What is Danaher Corp.’s market cap?
Danaher Corp.’s market cap is $156.25B.
When is Danaher Corp.’s upcoming earnings report date?
Danaher Corp.’s upcoming earnings report date is Feb 04, 2026 which is in 78 days.
How were Danaher Corp.’s earnings last quarter?
Danaher Corp. released its earnings results on Oct 21, 2025. The company reported $1.89 earnings per share for the quarter, beating the consensus estimate of $1.722 by $0.168.
Is Danaher Corp. overvalued?
According to Wall Street analysts Danaher Corp.’s price is currently Undervalued.
Does Danaher Corp. pay dividends?
Danaher Corp. pays a Quarterly dividend of $0.32 which represents an annual dividend yield of 0.56%. See more information on Danaher Corp. dividends here
What is Danaher Corp.’s EPS estimate?
Danaher Corp.’s EPS estimate is 2.14.
How many shares outstanding does Danaher Corp. have?
Danaher Corp. has 706,349,550 shares outstanding.
What happened to Danaher Corp.’s price movement after its last earnings report?
Danaher Corp. reported an EPS of $1.89 in its last earnings report, beating expectations of $1.722. Following the earnings report the stock price went up 5.941%.
Which hedge fund is a major shareholder of Danaher Corp.?
Currently, no hedge funds are holding shares in DHR
Danaher Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$243.45 (10.05% Upside)
$243.45 (10.05% Upside)
Blogger Sentiment
Bullish
DHR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 796.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $235.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 4.2%
Last 30 Days ▲ 4.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-7.02%
12-Months-Change
Fundamentals
Return on Equity
6.84%
Trailing 12-Months
Asset Growth
-0.89%
Trailing 12-Months
Company Description
Danaher Corp.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
DHR Company Deck
DHR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Danaher Corporation reported strong financial performance with notable growth in the bioprocessing segment and successful new product launches. However, challenges in China and a decline in Life Sciences and equipment revenue were highlighted as areas of concern. Overall, the company is optimistic about overcoming these challenges and maintains a positive outlook for the future.View all DHR earnings summariesDHR Revenue Breakdown
40.99% Diagnostics
30.70% Life Sciences
28.31% Biotechnology
DHR Stock 12 Month Forecast
Average Price Target
$243.45
▲(10.05% Upside)
Technical Analysis
Ownership Overview
8.81% Insiders
26.45% Mutual Funds
10.70% Other Institutional Investors
34.49% Public Companies and Individual Investors